By targeting key signaling pathways such as IL-6/STAT3, autophagy, glycolysis, and Wnt/β-catenin, as well as by modulating the tumor microenvironment, ginsenosides enhance the efficacy of chemotherapy drugs in cancer types that exhibit resistance, including breast, lung, pancreatic cancers, and glioblastoma. This evidence concerns the gene IL6 and familial pancreatic carcinoma.